{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.068","value":"1.08"},{"groupId":"OG001","spread":"20.430","value":"-1.21"}]}],"title":"Week 5 Day 1 (Day 29)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.265","value":"7.24"},{"groupId":"OG001","spread":"24.947","value":"3.59"}]}],"title":"Week 25 Day 1 (Day 169)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.787","value":"6.54"},{"groupId":"OG001","spread":"27.051","value":"2.59"}]}],"title":"Week 49 Day 1 (Day 337)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Blood samples were collected from participants for hormonal measurements.","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337)","title":"Percent Change From Baseline In Serum Concentrations Of Sex Hormone-Binding Globulin","type":"SECONDARY","unitOfMeasure":"percent change"}